Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSCs for AVF Stenosis in Diabetic Kidney Disease
NCT07452822Phase 2Not yet recruiting
- Sponsor
- Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, open-label trial of human umbilical cord mesenchymal stem cells in arteriovenous fistula stenosis (2 arms), sponsored by Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity at 28 days and Efficacy in preventing stenosis at 3 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
arteriovenous fistula stenosis
Beyond the preview
Go deeper on NCT07452822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07452822.